Want to see HCAT full AI Analyst Report?

Health Catalyst (HCAT) Stock Forecast & Price Target

461 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HCAT Analyst Ratings

Hold

1 Buy

5 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Health

Catalyst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HCAT Stock 12 Month Forecast

Average Price Target

$1.83

▲(14.78% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $1.83 with a high forecast of $2.00 and a low forecast of $1.50. The average price target represents a 14.78% change from the last price of $1.59.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,1.7323076923076923,1.7546153846153847,1.7769230769230768,1.7992307692307692,1.8215384615384616,1.843846153846154,1.866153846153846,1.8884615384615384,1.9107692307692308,1.9330769230769231,1.9553846153846153,1.9776923076923076,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,1.718846153846154,1.7276923076923076,1.7365384615384616,1.7453846153846153,1.7542307692307693,1.763076923076923,1.771923076923077,1.7807692307692307,1.7896153846153846,1.7984615384615383,1.8073076923076923,1.816153846153846,{"y":1.825,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.71,1.6938461538461538,1.6776923076923076,1.6615384615384614,1.6453846153846154,1.6292307692307693,1.613076923076923,1.596923076923077,1.5807692307692307,1.5646153846153845,1.5484615384615386,1.5323076923076924,1.5161538461538462,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$2.00

Average Price Target$1.83

Lowest Price Target$1.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Close

Canaccord Genuity

$3→$1.8

Hold

13.21%

Upside

Downgraded

08/21/26

Health Catalyst downgraded to Hold from Buy at CanaccordHealth Catalyst downgraded to Hold from Buy at Canaccord

David Larsen

BTIG

―

Hold

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Viridian Therapeutics (NASDAQ: VRDN)

Stan Berenshteyn

Wells Fargo

$1.75→$1.5

Hold

-5.66%

Downside

Assigned

08/13/26

Wells Fargo Issues a Hold Rating on Health Catalyst (HCAT)

Daniel Grosslight

Citi

$2.5→$2

Hold

25.79%

Upside

Reiterated

08/10/26

Health Catalyst (HCAT) Receives a Hold from Citi

David Grossman

Stifel Nicolaus

Hold

25.79%

Upside

Reiterated

08/07/26

Health Catalyst (HCAT) Gets a Hold from Stifel Nicolaus

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jessica Tassan

Piper Sandler

Hold

25.79%

Upside

Reiterated

05/12/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Health Catalyst (NASDAQ: HCAT) and Gain Therapeutics (NASDAQ: GANX)

Jeffrey Garro

Stephens

$2→$1.75

Hold

10.06%

Upside

Reiterated

05/12/26

Health Catalyst price target lowered to $1.75 from $2 at StephensHealth Catalyst price target lowered to $1.75 from $2 at Stephens

Sarah James

Cantor Fitzgerald

Hold

88.68%

Upside

Reiterated

05/08/26

Cantor Fitzgerald Reaffirms Their Hold Rating on Health Catalyst (HCAT)

Elizabeth Anderson CFA

Evercore ISI

Hold

88.68%

Upside

Reiterated

03/30/26

Evercore ISI Reaffirms Their Hold Rating on Health Catalyst (HCAT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Close

Canaccord Genuity

$3→$1.8

Hold

13.21%

Upside

Downgraded

08/21/26

Health Catalyst downgraded to Hold from Buy at CanaccordHealth Catalyst downgraded to Hold from Buy at Canaccord

David Larsen

BTIG

―

Hold

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Viridian Therapeutics (NASDAQ: VRDN)

Stan Berenshteyn

Wells Fargo

$1.75→$1.5

Hold

-5.66%

Downside

Assigned

08/13/26

Wells Fargo Issues a Hold Rating on Health Catalyst (HCAT)

Daniel Grosslight

Citi

$2.5→$2

Hold

25.79%

Upside

Reiterated

08/10/26

Health Catalyst (HCAT) Receives a Hold from Citi

David Grossman

Stifel Nicolaus

Hold

25.79%

Upside

Reiterated

08/07/26

Health Catalyst (HCAT) Gets a Hold from Stifel Nicolaus

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jessica Tassan

Piper Sandler

Hold

25.79%

Upside

Reiterated

05/12/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Health Catalyst (NASDAQ: HCAT) and Gain Therapeutics (NASDAQ: GANX)

Jeffrey Garro

Stephens

$2→$1.75

Hold

10.06%

Upside

Reiterated

05/12/26

Health Catalyst price target lowered to $1.75 from $2 at StephensHealth Catalyst price target lowered to $1.75 from $2 at Stephens

Sarah James

Cantor Fitzgerald

Hold

88.68%

Upside

Reiterated

05/08/26

Cantor Fitzgerald Reaffirms Their Hold Rating on Health Catalyst (HCAT)

Elizabeth Anderson CFA

Evercore ISI

Hold

88.68%

Upside

Reiterated

03/30/26

Evercore ISI Reaffirms Their Hold Rating on Health Catalyst (HCAT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Health Catalyst

3 Months

Ryan DanielsWilliam Blair

Success Rate

2/12 ratings generated profit

Average Return

-13.43%

Copying Ryan Daniels's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -13.43% per trade.

1 Year

Ryan DanielsWilliam Blair

Success Rate

2/12 ratings generated profit

Average Return

-35.00%

Copying Ryan Daniels's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -35.00% per trade.

2 Years

Ryan DanielsWilliam Blair

Success Rate

3/12 ratings generated profit

Average Return

-31.25%

Copying Ryan Daniels's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -31.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HCAT Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HCAT has received 2 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. HCAT average Analyst price target in the past 3 months is 1.83.

Each month's total comprises the sum of three months' worth of ratings.

HCAT Financial Forecast

HCAT Earnings Forecast

Next quarter’s earnings estimate for HCAT is -$0.05 with a range of -$0.08 to -$0.02. The previous quarter’s EPS was $0.04. HCAT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.

HCAT Sales Forecast

Next quarter’s sales forecast for HCAT is $55.44M with a range of $55.08M to $55.85M. The previous quarter’s sales results were $70.49M. HCAT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HCAT has Performed in-line its overall industry.

HCAT Stock Forecast FAQ

What is HCAT’s average 12-month price target, according to analysts?

Based on analyst ratings, Health Catalyst’s 12-month average price target is 1.83.

What is HCAT’s upside potential, based on the analysts’ average price target?

Health Catalyst has 14.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HCAT a Buy, Sell or Hold?

Health Catalyst has a consensus rating of Hold which is based on 1 buy ratings, 5 hold ratings and 0 sell ratings.

What is Health Catalyst’s price target?

The average price target for Health Catalyst is 1.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $1.50. The average price target represents 14.78% Increase from the current price of $1.59.

What do analysts say about Health Catalyst?

Health Catalyst’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of HCAT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Health Catalyst (HCAT) Stock Forecast & Price Target

HCAT Analyst Ratings

HCAT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Health Catalyst

HCAT Analyst Recommendation Trends

HCAT Financial Forecast

HCAT Earnings Forecast

HCAT Sales Forecast

HCAT Stock Forecast FAQ

Detailed List of Analyst Forecasts